Filing Flows › TScan Therapeutics (TCRX) › Q1 2026 › vs Q1 2025
TScan Therapeutics (TCRX) Q1 2026 vs Q1 2025 (year over year)
TScan Therapeutics's revenue fell $1.2M (-55%) from $2.2M in Q1 2025 to $982K in Q1 2026.
TScan Therapeutics, Q1 2026: revenue $982K (-55% year over year), net loss $28.7M, operating cash flow −$24.3M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $982K | $2.2M | −$1.2M | -55% |
| Other income, net | $473K | $2.1M | −$1.6M | -78% |
| Net loss | $28.7M | $34.1M | −$5.5M | -16% |
| Costs & expenses | $30.1M | $38.4M | −$8.3M | -22% |
| Operating costs | $30.1M | $38.4M | −$8.3M | -22% |
| Research & development | $21.9M | $29.8M | −$7.9M | -26% |
| General & admin | $8.2M | $8.6M | −$416K | -5% |
| Operating cash sources | $28.7M | $34.1M | −$5.5M | -16% |
| Depreciation | $693K | $678K | $15K | +2% |
| Share-based compensation | $2.5M | $3.4M | −$949K | -28% |
| Working capital & other | $1.2M | −$7.6M | $8.8M | — |
| Cash used in operations | $24.3M | $37.6M | −$13.3M | -35% |
| Net loss absorbed | $28.7M | $34.1M | −$5.5M | -16% |
Questions
How much did TScan Therapeutics's revenue grow year over year in Q1 2026?
TScan Therapeutics's revenue fell $1.2M (-55%) from $2.2M in Q1 2025 to $982K in Q1 2026.